MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, November 17th. BTIG Research restated a “neutral” rating on shares of MaxCyte in a research note on Monday, August 11th. Finally, William Blair lowered MaxCyte from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.00.

MaxCyte Stock Performance

MXCT stock opened at $1.67 on Friday. The firm has a market cap of $178.15 million, a price-to-earnings ratio of -3.88 and a beta of 1.23. The firm has a 50-day simple moving average of $1.60 and a two-hundred day simple moving average of $1.84. MaxCyte has a one year low of $1.26 and a one year high of $5.20.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%.The firm had revenue of $6.41 million during the quarter, compared to analysts’ expectations of $8.37 million. As a group, equities analysts predict that MaxCyte will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Institutional investors have recently modified their holdings of the business. Moors & Cabot Inc. increased its stake in shares of MaxCyte by 34.4% in the 1st quarter. Moors & Cabot Inc. now owns 17,708 shares of the company’s stock valued at $48,000 after purchasing an additional 4,528 shares in the last quarter. Hsbc Holdings PLC grew its holdings in MaxCyte by 9.8% in the first quarter. Hsbc Holdings PLC now owns 53,556 shares of the company’s stock valued at $144,000 after purchasing an additional 4,765 shares during the period. CWM LLC increased its position in shares of MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after buying an additional 5,836 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of MaxCyte by 2.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 299,734 shares of the company’s stock worth $818,000 after buying an additional 7,754 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of MaxCyte by 2.8% during the 1st quarter. Bank of New York Mellon Corp now owns 345,471 shares of the company’s stock valued at $943,000 after buying an additional 9,337 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.